As well as addressing whether VPA could boost the CD8 response against TAAs expressed by melanoma cells, we also considered whether HDAC inhibition might alter the expression of TAA by melanoma cells and potentially broaden the range of antigens available for CTL priming. The gene discussed is CD8A; the disease is melanoma.